Veradermics (NYSE: MANE) tops hair-loss trial endpoints in Study 304

What happened

Veradermics, Incorporated (NYSE: MANE) said VDPHL01 met all primary and secondary endpoints in its Phase 3 Study 304 of male pattern hair loss. The company said the oral extended-release minoxidil formulation posted high statistical significance in both once-daily and twice-daily arms.

Study 304 enrolled 536 participants. They were randomized to VDPHL01 8.5 mg once daily, VDPHL01 8.5 mg twice daily, or placebo. At Month 6, mean target area hair count rose 28.6 hairs cm in the once-daily arm and 36.4 hairs cm in the twice-daily arm, compared with 6.6 hairs cm for placebo. The company also said 78.8% and 85.0% of participants reported visible improvement, compared with 35.3% of placebo participants.

The company said hair growth was statistically different from placebo by Month 2, the first time point it checked. It also said more than 1,000 participants across two registration-directed studies showed no new safety signals, and that Study 304 looked consistent with Study 302.

Key numbers

Metric	Latest	Change	Source
Study 304 enrollment	536 participants		SEC 8-K Exhibit 99.1
Mean target area hair count increase, once-daily arm	28.6 hairs cm		SEC 8-K Exhibit 99.1
Mean target area hair count increase, twice-daily arm	36.4 hairs cm		SEC 8-K Exhibit 99.1
Mean target area hair count increase, placebo	6.6 hairs cm		SEC 8-K Exhibit 99.1
Visible improvement, once-daily arm	78.8%		SEC 8-K Exhibit 99.1
Visible improvement, twice-daily arm	85.0%		SEC 8-K Exhibit 99.1

Read more: Veradermics (MANE) stock analysis and investment case

Why it matters

OptimistFi's case is that Veradermics is a high-burn, late clinical-stage dermatology bet whose value depends on proving differentiated therapies and financing them to approval without crippling dilution. This filing supports that view by adding another placebo-controlled readout in the same male program and by matching the earlier Study 302 signal on the same endpoints.

Using OptimistFi's calculation from the filing's figures, visible improvement was 43.5 percentage points higher in the once-daily arm than in placebo at Month 6. The filing also says the program has now reported positive placebo-controlled data from two registration-directed trials that together enrolled more than 1,000 male participants.

The main risk is that these are topline results for an investigational drug. The filing says no head-to-head studies against finasteride or other forms of minoxidil have been done, and longer-term Study 302 Part B and Study 306 data are still pending.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

What's next

Veradermics said it will host a conference call and live webcast today at 8:00 a.m. ET. It also expects Part B data from Study 302 later this year and topline Study 306 data in the first half of 2027.

More data showing the response holds through the extension period would strengthen the case. Weaker follow-up data would weaken it.

More from OptimistFi

• MANE stock: the Veradermics thesis, its status and the next test to watch
• Stock research on every company OptimistFi covers

From OptimistFi Perps